John T Letsinger

US Patent:

59726806, Oct 26, 1999

Filed:

Sep 19, 1995

Appl. No.:

8/530792

Inventors:

William J. Knowles - Madison CT
Donna Guralski - Oxford CT
John T. Letsinger - West Haven CT
Wallace Haigh - Madison CT
John T. Hart - Wallingford CT
Kevin B. Clairmont - Cheshire CT

Assignee:

Bayer Corporation - Pittsburgh PA

International Classification:

C12N 950
C07H 2104

US Classification:

435219

Abstract:

An aminopeptidase which is a component of GLUT4-containing vesicles in the natural state, and which cleaves insulin. The claimed protein has an apparent molecular weight of approximately 110 kD in its deglycosylated form and a predicted molecular weight of 117,239 Daltons. It includes the amino acid sequences Phe-Ala-Ala-Thr-Gln-Phe-Glu-Pro-Leu-Ala-Ala (SEQ ID NO: 1) and Ile-Leu-Gln-Asn-Gln-Ile-Gln-Gln-Gln-Thr-Arg-Thr-Asp-Glu-Gly-Xaa-Pro-Xaa-Me t (SEQ ID NO: 2, and reacts with antibodies produced against the peptide identified as (SEQ ID NO: 1). It is encoded by the cDNA of FIG. 20 (SEQ. ID NOs. 15 and 16) and is essentially the protein sequence therein described. Modulators of the activity of the aminopeptidase and a method for treating syndromes of insulin resistance, including diabetes, by administration of such a modulator are also claimed.

US Patent:

59687649, Oct 19, 1999

Filed:

May 4, 1995

Appl. No.:

8/437116

Inventors:

William J. Knowles - Madison CT
Donna Guralski - Oxford CT
Wallace Haigh - Madison CT
John T. Letsinger - West Haven CT

Assignee:

Bayer Corporation - Pittsburgh PA

International Classification:

C12Q 137

US Classification:

435 24

Abstract:

An aminopeptidase which is a component of GLUT4-containing vesicles in the natural state, and which cleaves insulin. The claimed protein has a molecular weight of approximately 110 kD in its deglycosylated form. It includes the amino acid sequences Phe-Ala-Ala-Thr-Gln-Phe-Glu-Pro-Leu-Ala-Ala [SEQ ID NO: 1] and Ile-Leu-Gln-Asn-Gln-Ile-Gln-Gln-Gln-Thr-Arg-Thr-Asp-Glu-Gly-Xaa-Pro-Xaa-Me t [SEQ ID NO: 2], and reacts with antibodies produced against the peptide identified as [SEQ ID NO: 1]. Modulators of the activity of the aminopeptidase and a method for treating syndromes of insulin resistance, including diabetes, by administration of such a modulator are also claimed.